InvestorsHub Logo
Followers 45
Posts 892
Boards Moderated 0
Alias Born 12/01/2010

Re: Alan Brochstein post# 1540

Friday, 03/24/2017 2:42:10 PM

Friday, March 24, 2017 2:42:10 PM

Post# of 44032
Alan, the fact that you bring up GW Pharma suggests you still don't understand our business plan.

Texas has a horrible program - CBD for epilepsy only initially. The program goes live about the same time GW Pharma could have Epidiolex on the market. Their drug, if approved, would have FDA approval and insurance reimbursement, making the limited Texas program really uncompetitive. In addition, while they operate in the grey, there are lots of providers of CBD from industrial hemp grown overseas or domestically.



GW Pharma produces a single molecule compound formula. We're setting up to do precision expression of the entourage effect. We're setting up to offer personalized medicine based on the entourage effect, not single molecule compounds. It's like comparing apples to oranges Alan. My advice is do some research on the "entourage affect".

If you're not using precision cultivation methods like we've developed, you simply can not control with precision the chemical expression. It's what we learned and developed in our relationship with MIT.

If you actually made an effort to understand what we're doing on the science side, you might learn that we're on the cutting edge of cannabis research and development for pharmaceuticals.

It is our ability to "augment" the production of cannabis as stated by the DEA, which is looking for such a producer, that is driving our efforts.

It's a shame that the company was never able to generate sales into the cannabis industry. I thought that they would, but, for whatever reason, they have been slow to prove out acceptance of their technology beyond Canopy Growth.



The cannabis industry in the U.S. is under a cloud of uncertainty. Our technology costs 5X's more in CAPEX, but we offer 80% reduction in cost of goods and 50% increase in production. Simply put, cannabis growers and investors haven't embraced our methods because it requires an infrastructure investment industry players are afraid to make.

So we're simply going to keep it to ourselves and become a producer since the DEA opened the door for us to do so last August. All of this is explained in our public Deck.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INQD News